# EDGAR Filing Document

**Accession Number:** 0001832511
**File Stem:** 0001832511-25-000028
**Filing Date:** 2025-11
**Character Count:** 6196
**Document Hash:** 15c4694cf69a94224612dfd8e31f2950
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001832511-25-000028.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001832511-25-000028

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251121

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** P3 Health Partners Inc.
- **CENTRAL INDEX KEY:** 0001832511
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 852992794
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40033
- **FILM NUMBER:** 251534599

**BUSINESS ADDRESS:**
- **STREET 1:** 2045 W GRAND AVE STE B
- **STREET 2:** PMB # 82152
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60612-1577
- **BUSINESS PHONE:** 312-822-8897

**MAIL ADDRESS:**
- **STREET 1:** 2045 W GRAND AVE STE B
- **STREET 2:** PMB # 82152
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60612-1577

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Foresight Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201116

?xml version='1.0' encoding='ASCII'? piii-20251121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 21, 2025**

![P3HP_Logo.jpg](piii-20251121_g1.jpg)

**P3 Health Partners Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40033** | **85-2992794** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **2370 Corporate Circle Suite 300 Henderson, Nevada**  | **89074** |
| (Address of principal executive offices) | (Zip Code) |

---

**(702) 910-3950**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| **Class A common stock, par value $0.0001 per share** | **PIII** | **The Nasdaq Stock Market LLC** |
| **Warrants exercisable for one share of Class A common stock** | **PIIIW** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

------

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.** 

On November 21, 2025, P3 Health Partners Inc. (the "Company") received a letter (the "Letter") from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which notified the Company that it does not presently comply with Nasdaq's Listing Rule 5550(b)(1) (the "Listing Rule"), which requires that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule.

The Letter does not have any immediate effect on the listing of the Company's common stock or warrants on Nasdaq, and the Company has 45 calendar days to submit a plan to regain compliance. If the Company's plan is accepted, the Staff may grant an extension of up to 180 calendar days from November 21, 2025 to evidence compliance. After review of the plan of compliance, the Staff will provide written notification to the Company as to whether it accepts the plan, and if the Staff does not accept the plan, the Company would then be entitled to appeal the Staff's determination to the Nasdaq Hearings Panel. There can be no assurance that any such appeal would be successful.

The Company intends to submit its plan to remediate the listing qualification deficiency within the required timeframe and is actively pursuing the steps necessary to restore compliance. Management firmly believes in the long-term value-creation opportunity of the business and remains committed to executing against the initiatives that support sustainable growth and achieving profitability.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **P3 Health Partners Inc.** |
| Date: | November 28, 2025 | By: | /s/ Leif Pedersen |
|  |  |  | Leif Pedersen |
|  |  |  | Chief Financial Officer |

---